The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
Chiara Molinelli(Ospedale Policlinico San Martino), Lucia Del Mastro(Ospedale Policlinico San Martino), Fabio Puglisi(University of Udine), Claudia Bighin(Azienda Ospedaliera S.Maria), Eva Blondeaux(Ospedale Policlinico San Martino), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), Marco Bruzzone(Ospedale Policlinico San Martino), Tommaso Ruelle(Ospedale Policlinico San Martino), Valentina Sini(Ospedale di Santo Spirito), Stefania Russo(National Center for Oncological Hadrontherapy), Matteo Lambertini(Ospedale Policlinico San Martino), Chiara Lanzavecchia(Ospedale Policlinico San Martino), Alessandra Fabi(Agostino Gemelli University Polyclinic), Andrea Fontana(Azienda Ospedaliera Universitaria Pisana), Francesco Cognetti(National Cancer Institute), Elena Collovà(Aziende Socio Sanitarie Territoriale Ovest Milanese), Palma Pugliese(Ospedale Sant'Anna), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 15
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Cancer and fertility preservation: international recommendations from an expert meeting
|BMC Medicine|2016|779